The mTOR inhibitors Everolimus and Temsirolimus have been approved by the FDA, EMA and PMDA for use in some indications, and clinical trials of these and other mTOR inhibitors as well as inhibitors of PI3K and Akt are currently underway in multiple tumor types [58,59]. The gene discussed is PIK3CA; the disease is neoplasm.